Metagenomi to Present New Preclinical Data at the Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Tags:
Preclinical
Cell Therapy
EMERYVILLE, Calif.--(BUSINESS WIRE)--Metagenomi, a genetic medicines company with a versatile portfolio of next-generation gene editing tools, today announced that two presentations will be made at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, taking place virtually and in Washington, D.C., May 16-19, 2022.
Poster Details:
CRISPR-Associated Gene-Editing Systems Discovered in Metagenomic Samples Enable Efficient Genome Engineering in Multiple Primary Immune Cell Types
Poster number: Tu-60
Session Title: Gene Targeting and Gene Correction II
Location: Hall D
Presenting Author(s): Gregory J. Cost, PhD, Senior Director of Biology at Metagenomi
Date and Time: Tuesday, May 17, 2022 from 5:30 – 6:30 p.m. ET
Active CRISPR-Associated Transposases from Natural Environments
Poster number: Tu-68
Session Title: Gene Targeting and Gene Correction II
Location: Hall D
Presenting Author(s): Jason Liu, PhD, Scientist at Metagenomi
Date and Time: Tuesday, May 17, 2022 from 5:30 – 6:30 p.m. ET
Full abstracts are available on the ASGCT meeting website.
About Metagenomi
Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines and can be leveraged by partners. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co/.
Contacts
Investor: Simon Harnest CIO, SVP Strategy simon@metagenomi.co (917) 403-1051
Media: Ashlye Hodge Sr. Marketing and Communications Specialist ashlye@metagenomi.co (510) 734-4409
Investor: Simon Harnest CIO, SVP Strategy simon@metagenomi.co (917) 403-1051
Media: Ashlye Hodge Sr. Marketing and Communications Specialist ashlye@metagenomi.co (510) 734-4409
